Your browser doesn't support javascript.
loading
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières, J; Barlesi, F; Filleron, T; Besse, B; Monnet, I; Beau-Faller, M; Peters, S; Dansin, E; Früh, M; Pless, M; Rosell, R; Wislez, M; Fournel, P; Westeel, V; Cappuzzo, F; Cortot, A; Moro-Sibilot, D; Milia, J; Gautschi, O.
Afiliación
  • Mazières J; Thoracic Oncology Unit, Larrey Hospital, Centre Hospitalier Universitaire de Toulouse, Toulouse University III (Paul Sabatier), Toulouse mazieres.j@chu-toulouse.fr.
  • Barlesi F; Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille.
  • Filleron T; Clinical Research Unit, Biostatistics, Cancer University Institute of Toulouse Oncopole, Toulouse.
  • Besse B; Thoracic Oncology Section, Gustave Roussy Cancer Campus, Villejuif.
  • Monnet I; Pulmonology Department, Centre hospitalier intercommunal, Créteil.
  • Beau-Faller M; Chest Department, Strasbourg University Hospital, Strasbourg, France.
  • Peters S; Medical Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
  • Dansin E; Medical Oncology Department, Centre Oscar Lambret, Lille, France.
  • Früh M; Department of Oncology and Hematology, Cantonal Hospital of St Gallen, St Gallen.
  • Pless M; Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Rosell R; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Wislez M; Pulmonary Medicine Unit, AP-HP, Hôpital Tenon, Paris.
  • Fournel P; Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez.
  • Westeel V; Pulmonology Department, Centre Hospitalier Régional Universitaire, Hôpital Jean Minjoz, Besançon, France.
  • Cappuzzo F; Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy.
  • Cortot A; Pulmonology Department, Centre Hospitalier Universitaire, Lille.
  • Moro-Sibilot D; Department of Thoracic Oncology, Centre Hospitalier Universitaire, Grenoble, France.
  • Milia J; Thoracic Oncology Unit, Larrey Hospital, Centre Hospitalier Universitaire de Toulouse, Toulouse University III (Paul Sabatier), Toulouse.
  • Gautschi O; Medical Oncology, Cantonal Hospital Luzern, Luzern, Switzerland.
Ann Oncol ; 27(2): 281-6, 2016 Feb.
Article en En | MEDLINE | ID: mdl-26598547
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Molecular Dirigida / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Molecular Dirigida / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article